Peer-reviewed veterinary case report
Dog with metastatic anal sac cancer treated with chemo and COX-2
By N.C.T. Teixeira et al.·Published in Arquivo Brasileiro de Medicina Veterinária e Zootecnia·2016·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Ciclooxygenase inhibitor and metronomic chemotherapy association for the treatment of metastatic anal sac carcinoma in dog: case report
- Species:
- dog
Plain-English summary
A 10-year-old female mixed-breed dog was diagnosed with anal sac cancer that had spread to her lymph nodes. After surgery and initial chemotherapy with gemcitabine and carboplatin, she received a special type of ongoing chemotherapy called metronomic chemotherapy, along with a COX-2 inhibitor to help manage the cancer. Although the treatment was adjusted due to side effects, it proved effective, and the dog lived for over 36 months after starting this treatment, which is much longer than typically expected for this condition.
People also search for: dog anal sac cancer treatment · metronomic chemotherapy for dogs · COX-2 inhibitors in dogs
Abstract
ABSTRACT Metronomic chemotherapy consists of an anticancer modality treatment. It is applicable in patients at an advanced stage, with the objective of increasing overall survival. The aim of this study was to report an anal sac apocrine carcinoma case in a dog with lymph node metastasis treated with metronomic chemotherapy sequential to surgery and conventional chemotherapy using gemcitabine and carboplatin. Metronomic chemotherapy was associated with cyclooxygenase-2 (COX-2) inhibitors, due to strong tumor COX-2 immunohistochemistry expression. Metronomic chemotherapy was initiated with cyclophosphamide, but it was replaced by lomustine, also in metronomic dosage, due to adverse effects. Treatment showed effectiveness, since the patient's overall survival exceeded 1095 days (36 months), considerably higher than the mean overall survival expected for this pathology.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.1590/1678-4162-8439